AU
Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
$16.67 -0.24% (-$0.04)
1M +0.60%
Market Cap $2.14B
P/E Ratio 6.82x
Div. Yield -
ROE 59.00%
Bulios Fair Price
$18.21
9.2% upside
Current Price
$16.67
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AUPH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
80 /100
Cheap EV/EBITDA 10.76x
P/S 6.88x
P/B 3.49x
Growth
99 /100
Growing Book val. growth 12.76%
Rev. growth 28.30%
FCF growth N/A
Profitability
100 /100
Strong Net margin 100.84%
Op. margin 48.39%
FCF margin 55.72%
Quality
90 /100
Excellent ROE 59.00%
ROA 39.65%
Asset turnover 0.39x
Debt
100 /100
Low Current ratio 5.42x
Int. coverage 19.92x
Net debt/EBITDA -0.63x
Stability
46 /100
Moderate Rev. volatility 7.14%
EPS volatility 2,944.21%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AUPH
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Kevin C. Tang
Employees
128
Headquarters
Edmonton
Upcoming events
03 NOV
Earnings
Upcoming earnings report